HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

NCT05535933 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Warm Antibody Autoimmune Hemolytic Anemia

Interventions

DRUG: HMPL-523(300mg PO QD)
DRUG: Placebo

Sponsor

Hutchmed